Skip to main content
SpringerLink
Log in

Systemic T-cell lymphoma

  • Chapter
  • First Online:
Management of Lymphomas: A Case-Based Approach

  • 724 Accesses

Abstract

A 55-year-old man presents to his primary medical doctor with a 3 week history of fatigue, chills, and a ten pound unintentional weight loss. On examination, he is found to have several palpable nodes in his neck and right axilla. Excisional biopsy and workup including positron emission tomography (PET)/computed tomography (CT) confirms a diagnosis of peripheral T-cell lymphoma not otherwise specified (PTCL-nos), International Prognostic Index score (IPI) =3, and modified Prognostic Index for T-cell lymphoma (mPIT) =2 (+ R pleural effusion, lactate dehydrogenase [LDH] 2x upper limit of normal [ULN], Eastern Cooperative Oncology Group [ECOG] 1, ki67 80%).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974. 34:suppl:1488–1503.

    Google Scholar 

  2. Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26 Suppl 1:S71–S87.

    Google Scholar 

  3. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.

    Google Scholar 

  4. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non- Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717–720.

    Google Scholar 

  5. Bellei M, Chiattone CS, Luminari S, et al. T-cell lymphomas in South america and europe. Rev Bras Hematol Hemoter. 2012;34:42–47.

    Google Scholar 

  6. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49:2099–1107.

    Google Scholar 

  7. Rüdiger T, Ichinohasama R, Ott MM et al. Peripheral T-cell lymphoma with distinct perifollicular growth pattern: a distinct subtype of T-cell lymphoma? Am J Surg Pathol. 2000;24:117–122.

    Google Scholar 

  8. Warnke RA, Jones D, His ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol. 2007;127:511–527.

    Google Scholar 

  9. Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T-cell lymphoma with Reed- Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol. 1999;23:1233–1240.

    Google Scholar 

  10. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–4963.

    Google Scholar 

  11. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol. 2007;14:348–353.

    Google Scholar 

  12. Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and epsteinbarr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn. 2006;8:466–475; quiz 527.

    Google Scholar 

  13. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–1903.

    Google Scholar 

  14. Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.

    Google Scholar 

  15. O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–2499.

    Google Scholar 

  16. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189.

    Google Scholar 

  17. Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97:1594–1602.

    Google Scholar 

  18. Fabbri A, Cencini E, Pietrini A, et al. Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. Hematol Oncol. 2013;31:213–217.

    Google Scholar 

  19. Advani R, Horwitz S, Zelenetz A, Homing SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma. 2007;48:521–525.

    Google Scholar 

  20. Quintini G, Iannitto E, Barbera V, et al. Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol J. 2001;2:393–395.

    Google Scholar 

  21. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–3921.

    Google Scholar 

  22. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–5504.

    Google Scholar 

  23. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94:3509–3515.

    Google Scholar 

  24. Boddicker RL, Feldman AL. Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. Biomark Med. 2015;9:719–722.

    Google Scholar 

  25. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117: 915–919.

    Google Scholar 

  26. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–1480.

    Google Scholar 

  27. Roden AC, Macon WR, Keeney GL, et al. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol. 2008;21:455–463.

    Google Scholar 

  28. van der Veldt AA, Kleijn SA, Nanayakkara PW. Silicone breast implants and anaplastic large T-cell lymphoma. JAMA. 2009;301:1227; author reply 1227.

    Google Scholar 

  29. Santanelli di Pompeo F, Laporta R, Sorotos M, et al. Breast implant-associated anaplastic large cell lymphoma: proposal for a monitoring protocol. Plast Reconstr Surg. 2015;136:144e–151e.

    Google Scholar 

  30. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 1995;86:3619–3639.

    Google Scholar 

  31. Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood. 2001;97:3875–3881.

    Google Scholar 

  32. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177–4183.

    Google Scholar 

  33. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–842.

    Google Scholar 

  34. Phillips AA, Willim RD, Savage DG, et al. A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients. Leuk Lymphoma. 2009;50:1039–1042.

    Google Scholar 

  35. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–1741.

    Google Scholar 

  36. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–1376.

    Google Scholar 

  37. Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 20156;51:205–211.

    Google Scholar 

  38. Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opin Biol Ther. 2007;7:1869–1880.

    Google Scholar 

  39. Herrinton LJ, Liu L, Abramson O, Jaffe ES. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf. 2012;21:49–52.

    Google Scholar 

  40. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261–4269.

    Google Scholar 

  41. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009;20:1080–1085.

    Google Scholar 

  42. Voss MH, Lunning MA, Maragulia JC, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk. 2013;13:8–14.

    Google Scholar 

  43. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–155.

    Google Scholar 

  44. van de Water JM, Cillessen SA, Visser OJ, et al. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol. 2010;24:43–56.

    Google Scholar 

  45. Perry AM, Warnke RA, Hu Q, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122:3599–3606.

    Google Scholar 

  46. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/ delta subtypes. Am J Surg Pathol. 1998;22:881–893.

    Google Scholar 

  47. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: A clinical and follow-up study of 17 cases. J Am Acad Dermatol. 2000;42:208–213.

    Google Scholar 

  48. Kimura H. [EBV-positive T/NK lymphoproliferative disease in childhood]. Nihon Rinsho. 2012;70 Suppl 2:692–696.

    Google Scholar 

  49. Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta/ gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36:481–499.

    Google Scholar 

  50. Liang R. Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. Clin Lymphoma. 2000;1:33–37; discussion 38.

    Google Scholar 

  51. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/ T-cell lymphoma. Cancer Discov. 2012;2:591–597.

    Google Scholar 

  52. Ng SB, Yan J, Huang G, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011;118:4919–4929.

    Google Scholar 

  53. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104:243–249.

    Google Scholar 

  54. Lee J. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer. 2005;92:1226–1230.

    Google Scholar 

  55. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–618.

    Google Scholar 

  56. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21:1032–1040.

    Google Scholar 

  57. Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690–696.

    Google Scholar 

  58. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12:349–352.

    Google Scholar 

  59. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–2356.

    Google Scholar 

  60. Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30:4044–4046.

    Google Scholar 

  61. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27:6027–6032.

    Google Scholar 

  62. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120:2973–2980.

    Google Scholar 

  63. Tse E, Kwong Y-L. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997–5005.

    Google Scholar 

  64. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–4416.

    Google Scholar 

  65. Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drugs. 2013;31:469–472.

    Google Scholar 

  66. Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21:1058–1063.

    Google Scholar 

  67. Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant. 2009;44:709–714.

    Google Scholar 

  68. Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008;14:1356–1364.

    Google Scholar 

  69. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561–567.

    Google Scholar 

  70. Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2011;52:1255–1261.

    Google Scholar 

  71. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin lymphoma. https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed March 7, 2017.

  72. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475.

    Google Scholar 

  73. Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214.

    Google Scholar 

  74. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–3425.

    Google Scholar 

  75. d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–3099.

    Google Scholar 

  76. Dunleavy K, Pittaluga S, Shovlin M, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101:e27–29.

    Google Scholar 

  77. Dunleavy K, Shovlin M, Pittaluga S, et al. DA-EPOCH chemotherapy is highly effective in ALKpositive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults. Blood. 2011;118:1618.

    Google Scholar 

  78. Al-Toma A, Verbeek WH, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis. 2007;39:634–641.

    Google Scholar 

  79. Terras S, Moritz RK, Ditschkowski M, et al. Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous gamma/delta-T-cell lymphoma. Acta Dermato-Venereologica. 2013;93:360–361.

    Google Scholar 

  80. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–877.

    Google Scholar 

  81. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–2196.

    Google Scholar 

  82. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–3100.

    Google Scholar 

  83. Horwitz S. Second line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/ refractory peripehral T- cell lymphomas: minimal benefit when analyxed by intent to treat. Blood. 2005;106:2679.

    Google Scholar 

  84. Kogure Y, Yoshimi A, Ueda K, et al. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Ann Hematol. 2015;94:989–994.

    Google Scholar 

  85. Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104–110.

    Google Scholar 

  86. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.

    Google Scholar 

  87. Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869–2876.

    Google Scholar 

  88. Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–3109.

    Google Scholar 

  89. Le Gouill S, Milipied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–2271.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City of Hope National Medical Center, Duarte, California, USA

    Jasmine Zain

Authors
  1. Jasmine Zain
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. City of Hope Hospital, Duarte, California, USA

    Jasmine Zain

  2. Toni Stephenson Lymphoma Center, City of Hope Hospital, Duarte, California, USA

    Larry W. Kwak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Zain, J. (2017). Systemic T-cell lymphoma. In: Zain, J., Kwak, L. (eds) Management of Lymphomas: A Case-Based Approach. Adis, Cham. https://doi.org/10.1007/978-3-319-26827-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26827-9_11

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26825-5

  • Online ISBN: 978-3-319-26827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation